MO
TEVA icon

McMillan Office’s Teva Pharmaceuticals TEVA Stock Holding History

McMillan Office’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$382K Hold
12,675
– – 0.05% 137
2025
Q4 		$396K Buy
+12,675
New +$312K 0.05% 135

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

McMillan Office's TEVA Position: Q1 2026 in Review

McMillan Office held its Teva Pharmaceuticals (TEVA) position steady in Q1 2026 at 12,675 shares worth $382K. The position accounts for 0.05% of the portfolio, ranked #137.

McMillan Office first reported a position in TEVA in Q4 2025 and has held it in 2 quarters since. The position peaked at $396K in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • McMillan Office held 12,675 shares of Teva Pharmaceuticals worth $382K as of Q1 2026.
  • McMillan Office left its Teva Pharmaceuticals share count unchanged in Q1 2026.
  • Teva Pharmaceuticals made up 0.05% of McMillan Office's portfolio in Q1 2026, its #137 holding.
  • McMillan Office first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • McMillan Office's Teva Pharmaceuticals position peaked at $396K in Q4 2025.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on McMillan Office's 13F filing for Q1 2026, filed 23 Apr 2026.